Selective igg subclass deficiency and Paranasal sinus hypersecretion
Paranasal sinus hypersecretion is reported only by a few people with Selective igg subclass deficiency.
The study analyzes which people have Paranasal sinus hypersecretion with Selective igg subclass deficiency. It is created by eHealthMe based on 2 people who have Paranasal sinus hypersecretion and Selective igg subclass deficiency from the Food and Drug Administration (FDA), and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
2 people who have Selective Igg Subclass Deficiency and Paranasal Sinus Hypersecretion are studied.
What is Selective igg subclass deficiency?
Selective igg subclass deficiency (levels of one or two igg subclasses and a normal total igg level have a selective igg subclass deficiency) is found to be associated with 20 drugs and 9 conditions by eHealthMe.
What is Paranasal sinus hypersecretion?
Paranasal sinus hypersecretion is found to be associated with 729 drugs and 394 conditions by eHealthMe.
Number of Paranasal sinus hypersecretion in Selective igg subclass deficiency reports submitted per year:
Gender of people who have Selective Igg Subclass Deficiency and experienced Paranasal Sinus Hypersecretion *:
- female: 100 %
- male: 0.0 %
Age of people who have Selective Igg Subclass Deficiency and experienced Paranasal Sinus Hypersecretion *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 100 %
- 60+: 0.0 %
Common co-existing conditions for these people *:
- Immunodeficiency: 2 people, 100.00%
Common drugs taken by these people *:
- Zilretta: 2 people, 100.00%
- Vitamin D3: 2 people, 100.00%
- Nucynta: 2 people, 100.00%
- Magnesium: 2 people, 100.00%
- Lyrica: 2 people, 100.00%
- Humira: 2 people, 100.00%
- Heparin: 2 people, 100.00%
- Eliquis: 2 people, 100.00%
- Cymbalta: 2 people, 100.00%
- Calcium: 2 people, 100.00%
Common symptoms for these people *:
- Nasal Discharge Discoloration: 2 people, 100.00%
- Sinus Congestion (blockage of sinus): 2 people, 100.00%
- Paranasal Sinus Discomfort: 2 people, 100.00%
- Limb Injury: 1 person, 50.00%
- Burning Sensation: 1 person, 50.00%
- Discomfort: 1 person, 50.00%
- Fatigue (feeling of tiredness): 1 person, 50.00%
- Headache (pain in head): 1 person, 50.00%
- Infusion Related Reaction: 1 person, 50.00%
- Joint Pain: 1 person, 50.00%
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Paranasal sinus hypersecretion?Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Treatments, associated drugs and conditions:
COVID vaccines that are related to Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion in Moderna COVID Vaccine
- Paranasal sinus hypersecretion in Pfizer BioNTech Covid Vaccine
- Paranasal sinus hypersecretion in Johnson and Johnson Covid Vaccine
Common drugs associated with Paranasal sinus hypersecretion:
All the drugs that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (729 drugs)
Common conditions associated with Paranasal sinus hypersecretion:
All the conditions that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (394 conditions)
How the study uses the data?
The study is based on Paranasal sinus hypersecretion and Selective igg subclass deficiency, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Pepcid and Therapeutic Response Unexpected - 11 seconds ago
- Lymecycline and Spiriva drug interaction - 16 seconds ago
- How effective is Ranexa for Coronary Heart Disease? - 21 seconds ago
- Atacand and General Physical Health Deterioration - 35 seconds ago
- Fever and Gastrointestinal Inflammation - 47 seconds ago
- Carvedilol and Divalproex drug interaction - 49 seconds ago
- Dark Circles Under Eyes and drugs of ingredients of dorzolamide hydrochloride; timolol maleate - 53 seconds ago
- Drowsiness and drugs of ingredients of zolpidem tartrate - 58 seconds ago
- Percocet and Norflex drug interaction - a minute ago
- Renagel and Actemra drug interaction - a minute ago